Thymic Function Predicts Response to Mesenchymal Stromal Cell Treatment in Chronic GvHD: A Phase II Clinical Study

There is no established treatment for patients unresponsive to first line therapy for chronic graft versus host disease (cGVHD). Infusion of mesenchymal stromal cells (MSCs) is a promising alternative in this situation, but the treatment efficacy and mechanism of action have not yet been established. Furthermore, there is great need for biomarkers for selecting patients that are more likely to respond to MSC therapy.